Fidelity Advisor Global Equity Income Fund Class C (FGEHX) Cotización

$NVDA - Found support around the 20 week MA...
By: CyclesFan | December 22, 2024

• $NVDA - Found support around the 20 week MA. If it reverses from here and we get a bullish crossover on the True Strength Indicator, this week's low at 126.86 would become a weekly cycle low

Big Players buying the hot Blackwell NVDA GPUs......

Chipmaker NVIDIA recently announced that its latest Blackwell graphics processing units (GPUs) are sold out until the end of 2025, snapped up by the customers—including:
- Meta
- Microsoft
- Google
- Amaz

I don’t know what spells disaster better…
President Elon Musk or his protege Donald Trump.

I look forward to this stock cratering as the anticipated chaos emerges.

Nah, I'm not desperate. I'm just joking that understanding how our legal system works is really important for a functioning adult, and it really worries me that some of you lack this.

But that goes for the American members, you can do whatever you want in Brazil.

HUMBL sold its brand and technology assets to WSCG, Inc. for $20,000,000 in stock and cash. Thiago Moura, Chairman and CEO of Ybyra Capital, has now assumed the role of Chairman and CEO of HUMBL Inc. HUMBL acquired FinCapital, a subsidiary of Ybyra Capital, which includes $20,000,000 in physical ass

Again NWBO has the data on hundreds if not thousands of compassionate use cases. Every RA knows the magnitude of significance the statistics on these compassionate use cases carry. I am only concerned about when the approval will come. Seems very soon.

*****🟥🟥🟥 Several videos out by Marantz Rantzs proving AA was planted into 🚽AMC🚽 by Apollo -- a distressed credit investor

He actually connects the dots and ties AA to them

They destroy companies from within and exactly what's bee

And this is an interesting--and true--response:

https://x.com/Bill43111/status/1870900682116723010

This is in no way related to legacy chips.  Silicon is Maxed the F out.   As the saying goes let the chips fall where they may.

X tis a new AI game, crazy. Personally I'm not sure I like it but make some money and buy some  AI robots to do whatever.  Clean the roads, mow the lawn, go

Jim, I started ReMag right guy after my ablation in October. I mix with cranberry juice and have no issues with the taste. Won't have blood drawn until April so will see what results are. 

Here it is

https://x.com/acyn/status/1870899088633610384?s=46&t=HRw0TsA3C6qnjy6x_p3SQA

We may not know the exact price, but there is no way any country in the EU is paying $50K per year for 2-73. Maybe $20K...maybe. Probably half that. And rightly so.

BIEL miniaturized PEMF and their stock...COOL!🤠

BioElectronics market cap is forecast to decline 50% over the next year, this according to Sales-Track Market Research. 😎

$ADHC We should be hearing from the Company anytime now!
https://x.com/StockPicksNYC/status/1869797933484265670

........for Vegas.
1951-1962 was the time out there when the most atomic bomb testing occurred. You could get a hotel room (at a slightly higher cost for one on a higher floor facing in the direction of the Nevada Atomic Proving Grounds..The explosion of enriched uranium at night....millio

We're Interested To See How IonQ (NYSE:IONQ) Uses Its Cash Hoard To Grow
editorial-team@simplywallst.com (Simply Wall St)
Sun, December 22, 2024 at 9:01 AM EST 4 min read


In This Article:
IONQ
+17.64%
IONQ-WS
We can readily understand

SLOPCOIN IS LIKE GOLD SLOPCOIN IS LIKE GOLD!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! MUAHAHHAHAHAHAHAAHHAAHAHAHAHAHAHAHAHAHAHAH!!!!!!!!!!!!!!!!!!!!!!!!!! BRICS WILL RUN SLOPCOIN!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Oink Oink I get Chinease Buffett sometimes!! Oink Oink!!! come on HESG make mummy proud!! $30 to $60!! Oink OINK!!

Maybe anything speedy or even timely is a pipe dream.
"FDA leadership noted that Humacyte’s ATEV is a first-in-class product, and that Priority Review had been granted, which allows only a six-month review cycle, as compared to the standard ten-month review cycle for most products. During the

Northwest Biotherapeutics (NWBO) has a high probability of receiving MHRA approval for DCVax-L, at around 95%. This optimistic outlook is based on several factors:
The company submitted a Marketing Authorization Application (MAA) to the UK's Medicines and Healthcare products Regulatory Agency

Ridiculous that they didn’t buy those back,